CEimpact Podcast
The CEimpact Podcast features two shows:
GameChangers Clinical Updates
Precept2Practice
GameChangers Clinical Update Series:
The GameChangers podcast, hosted by Rachel Maynard, PharmD, features the latest game-changing pharmacotherapy advances impacting patient care. New episodes arrive every Monday. Listeners can purchase the episode to earn CE credit at: https://www.ceimpact.com/resources/podcast/
Precept2Practice
The Precept2Practice podcast, hosted by Kathy Schott, brings you tools to mentor students and residents with confidence. New episodes arrive on the third Wednesday of every month. Preceptor By Design™ subscribers can earn CE credit for each episode.
Give us a follow, tune in regularly, and turn your drive time, coffee break, or chart review into a chance to level up your practice. CEimpact continuing education makes pharmacy learning inspiring!
Check back each week for our latest episodes.
CEimpact Podcast
Is the Price Right for Aducanumab?
The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.
Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf
Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.